The lipoxygenase inhibitor nafazatrom inhibits stimulated prolactin secretion in cultured rat lactotrophs (GH4C1 cells)

Scand J Clin Lab Invest. 1992 Jun;52(4):297-303. doi: 10.3109/00365519209088362.

Abstract

Arachidonic acid metabolites are involved in the regulation of prolactin (PRL) secretion from rat lactotrophs (GH4C1 cells). Phospholipase A2 (PLA2) stimulated PRL secretion, while the PLA2 inhibitor quinacrine reduced both thyrotropin-releasing hormone (TRH) and vasoactive intestinal peptide (VIP) stimulated PRL release. Hormonally stimulated PRL release was further increased in the presence of the cyclo-oxygenase inhibitor indomethacin. Nafazatrom, a lipoxygenase inhibitor, reduced stimulated PRL secretion regardless of the mechanism of stimulation [hormonally (VIP and TRH) or by increasing intracellular Ca2+ concentration by KCl or Bay-K and cAMP by forskolin]. None of the inhibitors used in this study had any effect either on the basal PRL secretion or on the production of cAMP. Lipoxygenase products seem to be involved in the regulation of PRL secretion, probably by affecting a late step in the signal transduction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arachidonic Acid / metabolism
  • Cyclic AMP / metabolism
  • Lipoxygenase Inhibitors / pharmacology
  • Phospholipases A / pharmacology
  • Phospholipases A2
  • Pituitary Gland / drug effects*
  • Pituitary Gland / metabolism
  • Prolactin / metabolism*
  • Pyrazoles / pharmacology*
  • Pyrazolones*
  • Rats
  • Signal Transduction
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / metabolism

Substances

  • Lipoxygenase Inhibitors
  • Pyrazoles
  • Pyrazolones
  • Arachidonic Acid
  • Prolactin
  • Cyclic AMP
  • Phospholipases A
  • Phospholipases A2
  • nafazatrom